HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained an $87 price target. This reaffirms the firm's positive outlook on the company.
April 01, 2024 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reiterates a Buy rating on Legend Biotech with an $87 price target, indicating a strong positive outlook on the company's future.
The reiteration of a Buy rating and maintenance of an $87 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's prospects. This can positively influence investor sentiment and potentially lead to an uptick in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100